# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:MCK) with a Outperform and lowers the price target from $67...
- SEC Filing
McKesson Canada will continue to own and operate Rexall and Well.ca until transaction close, which is subject to customary clos...
Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claim...
FCS physicians will continue to retain a minority interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core ...
https://www.bloomberg.com/news/articles/2024-08-23/mckesson-nears-deal-for-stake-in-florida-cancer-chain?utm_content=business&a...
JP Morgan analyst Lisa Gill maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $656 to $661.